Loading...
The relation between cardiovascular (CV) risk and menopausal hormone therapy (MHT) is complex, and uncertainty persists. Although the original Women’s Health Initiative (WHI) trials showed excess cardiovascular risk among MHT users, follow-up analyses showed this effect was driven largely by MHT initiation in older women. In two recent studies, investigators further examined the relation between MHT and cardiovascular outcomes.
In another secondary analysis of WHI trial data, researchers compared incidence of adverse CV events among placebo recipients and recipients of MHT (oral conjugated equine estrogen (CEE) with or without oral medroxyprogesterone (MPA)]. Overall, MHT was not associated with excess CV risk. However, whe…